london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Association of baseline OCT thickness and final visual acuity 1 year after treatment for diabetic macular edema with ranibizumab

Poster Details

First Author: N.Unlu TURKEY

Co Author(s):    G. Uney   M.A. Acar   D. Hazirolan   F. Ornek         0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To identify the correlation of central macular thickness with visual outcome in patients with diabetic macular edema (DME) treated with ranibizumab.

Setting:

Department of Ophthalmology, Ankara Education and Research Hospital

Methods:

Eighty-two eyes with DME treated with ranibizumab were retrospectively reviewed. All underwent best-corrected visual acuity (BCVA) assessment and optical coherence tomography (OCT) at baseline, 3, 6 and 12 months. Patients were grouped according to the baseline central macular thickness (CMT) into2 groups. Group 1 had CMT <400µm (n=35), Group 2 CMT ≥400 µm (n=42).

Results:

At baseline mean visual acuity was 0,63±0.46 logMAR in group 1 and 0.72±0.39 logMAR in group 2. (p=0,199 Mann Whitney U) The BCVA was 0.37±0.45 logMAR in group 1 and 0.61±0.46 logMAR in group 2 (p<0.01) at twelveth month under ranibizumab treatment. Group 1 had a decrease in CMT by 17.9% compared with baseline and group 2 had 30.1%. Thirty eyes (85.75%) had BCVA ≥20/100 in group 1 compared with 35 (74.5%) in group 2. (p=0.104). The visual acuity was improved in 74.3% of eyes in group 1 and 54.7% of eyes in group 2, whereas visual acuity was unchanged in 22.9% and 25.5% respectively in groups.

Conclusions:

Ranibizumab was effective in improving and maintaining BCVA and CMT outcomes. Visual acuity improvement was less in cases with a thicker baseline CMT on OCT.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy